Dr. Joeri Kint

ExcellGene SA Monthey
Valais
Joeri Kint was trained in Biotechnology and BioProcess Development (University in Wageningen, MSc 2006). During his career at Intervet International B.V. (2006-2009) and Merck Animal Health (2009-2016) he contributed to the development of several veterinary vaccines for viral diseases such as coronavirus and Influenza. His PhD work (2010-2015) focused on the development of cell lines for the production of these vaccines, which are produced using embryonated chicken eggs. In 2016 he moved to Biotype GmbH, Dresden, Germany. Here he set-up a novel department for contract development and production of In Vitro Diagnostic tests for oncology and infectious diseases. Since 2020 he is Head of Business Development at ExcellGene SA, Monthey, Switzerland where he is responsible for the entire business in EU and Asia-Pacific, including all COVID-related product-development programs.

Events/Masterclasses Dr. Joeri Kint is currently speaking at

No events currently available.

Are you interested in a custom-made event with this trainer?

Contact us to Request more information about your custom-made Corporate Learning program.

REQUEST MORE INFORMATION

Dr. Joeri Kint
ExcellGene SA Monthey
Valais
Joeri Kint was trained in Biotechnology and BioProcess Development (University in Wageningen, MSc 2006). During his career at Intervet International B.V. (2006-2009) and Merck Animal Health (2009-2016) he contributed to the development of several veterinary vaccines for viral diseases such as coronavirus and Influenza. His PhD work (2010-2015) focused on the development of cell lines for the production of these vaccines, which are produced using embryonated chicken eggs. In 2016 he moved to Biotype GmbH, Dresden, Germany. Here he set-up a novel department for contract development and production of In Vitro Diagnostic tests for oncology and infectious diseases. Since 2020 he is Head of Business Development at ExcellGene SA, Monthey, Switzerland where he is responsible for the entire business in EU and Asia-Pacific, including all COVID-related product-development programs.
Dr. Joeri Kint
Description